Detalhe da pesquisa
1.
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.
Future Oncol
; 19(5): 345-353, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36815271
2.
A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Eur J Haematol
; 104(5): 435-442, 2020 May.
Artigo
Inglês
| MEDLINE | ID: mdl-31883396
3.
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.
J Hepatol
; 65(2): 280-8, 2016 08.
Artigo
Inglês
| MEDLINE | ID: mdl-26952006
4.
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
J Clin Oncol
; 40(1): 52-62, 2022 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34606378
5.
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.
Blood Adv
; 4(22): 5773-5784, 2020 11 24.
Artigo
Inglês
| MEDLINE | ID: mdl-33227125
6.
Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor.
J Clin Pharmacol
; 47(1): 26-36, 2007 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-17192499
7.
The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide.
J Clin Pharmacol
; 47(8): 1005-13, 2007 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-17660483
8.
Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity.
Clin Pharmacol Ther
; 79(4): 339-49, 2006 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-16580902
9.
Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects.
J Clin Pharmacol
; 46(10): 1146-53, 2006 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-16988203
10.
First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors.
Clin Cancer Res
; 19(19): 5494-504, 2013 Oct 01.
Artigo
Inglês
| MEDLINE | ID: mdl-24065624